Circulating exosomal miR-92b-5p is a promising diagnostic biomarker of heart failure with reduced ejection fraction patients hospitalized for acute heart failure

Abstract

Background: Circulating microRNA (miRNA) biomarkers have been extensively reported in cardiovascular diseases (CVDs). However, serum exosomal miRNA (exo-miRNA) as biomarker in patients with heart failure (HF) with reduced ejection fraction (HFrEF) remain largely unexplored. We sought to investigate the potential of three types of serum exo-miRNAs as biomarkers for diagnosis in HFrEF patients who were admitted in hospital because of acute heart failure (AHF). Methods: A total of 28 HFrEF patients hospitalized for AHF, including de novo AHF and acute decompensated HF, and 30 volunteers as control group (CG) from 2015 to 2017 were enrolled in this study. Serum exo-miRNAs were extracted and analyzed by NaNOZS-90, electron microscopy, and western blotting. Three types of serum exo-miRNAs (exo-miR-92b-5p,-192-5p, and-320a) were assessed by quantitative real time polymerase chain reaction (qRT-PCR). Results: The particle size was confirmed as 40-150 nm using NaNOZS-90 and transmission electron microscopy. Exosomal biomarkers CD63 and Hsp70 were readily detected. The expression level of serum exo-miRNAs were transformed into log2 −delta CT in the qPCR assay. The data showed that exo-miR-92b-5p was elevated in HFrEF patients compared with controls. Moreover, exo-miR-92b-5p was inversely correlated with the left ventricular fraction shortening (LVFS) and left ventricular ejection fraction (LVEF), whereas it was positively correlated with left atrial diameter (LAD), left ventricular diastolic diameters (LVDD) and systolic diameters (LVSD). A receiver operating characteristic (ROC) curve was generated for discrimination between HFrEF patients and controls based on exo-miR-92b-5p (P<0.001, sensitivity =71.4%, specificity =83.3%). Conclusions: Exo-miR-92b-5p levels in the serum may serve as a marker for HFrEF diagnosis.

Circulating exosomal microRNAs as emerging non‐invasive clinical biomarkers in heart failure: Mega bio‐roles of a nano bio‐particle

“…Similarly, another study was also shown that the serum level of Exo‐miR‐92b‐5p is significantly increased in HF with reduced ejection fraction (HFrEF) patients 138 . The levels of the serum Exo‐miR‐92b‐5p could discriminate HFrEF patients from healthy subjects with high sensitivity and specificity 138 .…”

“…139 Similarly, another study was also shown that the serum level of Exo-miR-92b-5p is significantly increased in HF with reduced ejection fraction (HFrEF) patients. 138 The levels of the serum Exo-miR-92b-5p could discriminate HFrEF patients from healthy subjects with high sensitivity and specificity. 138 Analysis of echocardiographic data revealed that the serum level of Exo-miR-92b-5p is negatively correlated with the function of the left ventricle, whereas it is positively correlated with dilation of the left ventricle.…”

“…138 Analysis of echocardiographic data revealed that the serum level of Exo-miR-92b-5p is negatively correlated with the function of the left ventricle, whereas it is positively correlated with dilation of the left ventricle. 138 Moreover, the increased plasma level of Exo-miR-92b was also found to define a score with high sensitivity and specificity for the discrimination of patients with the HFrEF relative to the healthy controls. Of note, the Exo-miR-92b score was indicated to associate with increased serum levels of natriuretic peptides as well as dilatation of the left ventricle and left atrium.…”

“…MMVD in dogs closely resembles MVP in humans with respect to structural and functional consequences, making this canine disease an attractive preclinical model. 151 It was reported that the plasma levels of Exo-miR-181c and Exo-miR-495 are significantly increased in dogs with MMVD-CHF compared to MMVD and normal dogs, revealing a role in initiation, progression, or Note: References: Beg et al 132 ; Goren et al 134 ; Halkein et al 135 ; Matsumoto et al 136 ; Wang et al 137 ; Wu et al 138 ; Wu et al 139 Abbreviation: Shox2, short stature homeobox 2.…”

“… Note : References: Beg et al 132 ; Goren et al 134 ; Halkein et al 135 ; Matsumoto et al 136 ; Wang et al 137 ; Wu et al 138 ; Wu et al 139 …”